Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

'Pharmaceutical Contract Manufacturing Market Will Reach $47.6 Billion in 2012' Predicts Visiongain Report


News provided by

Visiongain

11 Sep, 2012, 13:00 GMT

Share this article

Share toX

Share this article

Share toX

LONDON, September 11, 2012 /PRNewswire/ --

A new report by visiongain predicts that the world market for pharmaceutical contract manufacturing will be worth $47.6 billion in 2012. Between 2011 and 2016, the overall market will grow with a compound annual growth rate (CAGR) of over 6%. Demand for outsourcing will increase worldwide, driving revenue growth. Those findings and others appear in Pharmaceutical Contract Manufacturing: World Market Outlook 2012-2022, published in August 2012.

In 2011, active pharmaceutical ingredient (API) manufacturing services formed the largest market sector, accounting for more than two thirds of revenues. APIs will account for the majority of revenues throughout the coming 10 years. Increased demand for generic drugs will drive revenue growth for emerging-market contract manufacturing organisations (CMOs). Highly potent API (HPAPI) manufacturing will drive growth in the US and Europe. Increased outsourcing of finished dosage manufacturing will also stimulate developed-market growth. Development of biologics will increase demand for injectable dosage manufacturing services, including fill-finish and lyophilisation, the report also notes.

Richard Lang, a pharmaceutical industry analyst for visiongain, said: "Difficult economic conditions caused revenue to drop for many leading CMOs in recent years. Among the leading US and European market players, only a few achieved continuous revenue growth between 2009 and 2011. Many are now reporting an increased uptake of services, however. To remain competitive in the future, companies will need to react to trends in drug development. Companies investing in biologics manufacturing capacity will benefit from increased interest in this area."

Visiongain's study forecasts the leading national pharmaceutical contract manufacturing markets in terms of demand. In 2011, the leading national market was the US, accounting for over 40% of demand for outsourced manufacturing. Much of this demand is met by CMOs in the US and EU. However, pharmaceutical companies will increasingly use CMOs in India and China to supply APIs in the coming 10 years. Growth in national pharmaceutical markets in emerging countries will stimulate demand for outsourcing there. This demand will come from multinational companies seeking to enter the market, and domestic drug developers wanting to cut costs.

The updated report provides quantitative and qualitative analysis of the contract manufacturing industry and market. It shows revenue forecasts for leading sectors and national markets and identifies future trends that will affect companies. The work also discusses 20 leading CMOs, including Catalent, Lonza and Patheon.

Pharmaceutical Contract Manufacturing: World Market Outlook 2012-2022 adds to visiongain's portfolio of analytical reports covering pharmaceutical outsourcing and services markets. Visiongain is a business information provider based in London, UK.

For sample pages and further information concerning the Lyophilisation for Pharmaceuticals: Products and Services Market 2012-2022 please visit: http://www.visiongain.com/Report/880/Pharmaceutical-Contract-Manufacturing-World-Market-Outlook-2012-2022

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

Companies mentioned in the report include:


Abbott Contract Manufacturing (part of Abbott Laboratories)
Abbott Laboratories
ADVENTRX Pharmaceuticals
Aenova (formerly Dragenopharm Apotheker Püschl and Swiss Caps)
Aesica Pharmaceuticals
Agência Nacional de Vigilância Sanitária (ANVISA) [Brazil]
Agennix
Albany Molecular Research (AMRI)
Alexion Pharmaceuticals
Amgen
Aptuit
Athera Biotechnologies
Avalanche Biotechnologies
AVEO Pharmaceuticals
Avesthagen
BASF
Ben Venue Laboratories (part of Boehringer Ingelheim)
Bend Research
Biogen Idec
Blackstone Group
Boehringer Ingelheim
Bristol-Myers Squibb
Cambridge Major Laboratories (CML)
Cardinal Health
Catalent
Celltrion
Centocor (now known as Janssen Biologics)
CMIC CMO
Cobra Biologics Holding
Daiichi Sankyo
Department of Pharmaceuticals [India]
Divis Laboratories
Dr. Reddy's Laboratories
DSM Sinochem Pharmaceuticals (DSP)
Eclipse Therapeutics
Elan
Eli Lilly
Emcure Pharmaceuticals
Enobia Pharma (part of Alexion Pharmaceuticals)
European Commission (EC)
European Medicines Agency (EMA)
Evonik Degussa (part of Evonik Industries)
Evonik Industries
Famar
Fareva
Farmhispania
FDA Office of Combination Products (OCP) [US]
Food and Drug Administration (FDA) [US]
Frazier Healthcare
Gallus BioPharmaceuticals
GEA Lyophil
Government Accountability Office (GAO) [US]
GSK
Halo Pharmaceuticals
Haupt Pharma
Hikal
Hospira
Hospira One 2 One (part of Hospira)
Human Genome Sciences (part of GSK)
Immune Pharmaceuticals
Infa Group
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)
Jubilant HollisterStier (part of Jubilant Life Sciences)
Jubilant Life Sciences
Kemwell Biopharma
Kensey Nash
Korea Food and Drug Administration (KFDA)
Lonza
Marinopoulos Group
Medicines and Healthcare Products Regulatory Agency (MHRA) [UK]
Mesoblast
Ministry of Health, Labor and Welfare (MHLW) [Japan]
MorphoSys
Nascent Biologics
NextPharma Technologies
Nipro
NKT Therapeutics
Novartis
Nycomed (part of Takeda Pharmaceutical)
Pantec
Patheon
Pfizer
Pfizer CentreSource (part of Pfizer)
Pharmaceutical Research and Manufacturers of America (PhRMA)
Pharmaceuticals and Medical Devices Agency (PMDA) [Japan]
Piramal Healthcare
ProBioGen
Procaps
QRxPharma
Quintiles
R5 (part of Aesica Pharmaceuticals)
Recepta Biopharma
Recipharm
RecipharmCobra Biologics (part of Cobra Biologics Holding)
Roche
Royal DSM
SafeBridge Consultants
Samsung
Samsung BioLogics
Sanofi
SCM Pharma
Seattle Genetics
Sigmar Italia (part of Fareva)
Silverfleet Capital
Sinochem
SkyePharma
State Food and Drug Administration (SFDA) [China]
Sun Capital Partners
SurModics (part of Evonik Industries)
Swedbank
Teva Pharmaceutical Industries
Therapeutic Goods Administration (TGA) [Australia]
UCB
Uquifa
Vetter Pharma-Fertigung
Vivante GMP Solutions (part of Lonza)
Wasserburger Arzneimittelwerk (part of Recipharm)
Wockhardt
World Health Organization (WHO)
Xencor 

For an executive summary of this report or to order it today please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com
Tel: +44(0)20-7336-6100

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44(0)207-336-6100

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.